Turning Point Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO–(BUSINESS WIRE)–Turning Point Therapeutics, Inc. (Nasdaq:TPTX), a clinical-stage precision oncology company designing and developing novel drugs to address treatment resistance, today announced the pricing of its initial public offering […]